Recurrent Glioblastoma Clinical Trials

30 studies are recruiting for recurrent glioblastoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

   The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the bloo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Phoenix, Arizona

   Locations

   56 in total

   Run by

   CarThera

   See if you can join NCT05902169 on ClinicalTrials.gov

2. Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

   * To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer [18F]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   2 in total

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT06613841 on ClinicalTrials.gov

3. A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

   The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   9 in total

   Run by

   Boston Scientific Corporation

   See if you can join NCT05303467 on ClinicalTrials.gov

4. Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma

   This early phase I trial tests the safety, best dose, and effectiveness of SONALA-001 or 5-ALA HCL in combination with magnetic resonance imaging-guided focused ultrasound (MRgFUS), also called sonodynamic therapy, in treating patients with glioblastoma that is growing, spreading, or getting worse …

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT07076472 on ClinicalTrials.gov

5. A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

   To find the best method of administering NK cells in patients with recurrent glioblastoma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07579208 on ClinicalTrials.gov

6. BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma

   This Phase 1 study will assess the safety of a novel brain Bispecific T cell engager (BRiTE) in patients with newly diagnosed or recurrent World Health Organization (WHO) Grade 4 glioblastoma (GBM). Owing to its short half-life, the study drug, BRiTE, will be continuously infused intravenously (IV)…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Run by

   Mustafa Khasraw, MBChB, MD, FRCP, FRACP

   See if you can join NCT04903795 on ClinicalTrials.gov

7. Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

   Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within months or years after treatment, and when they do, they are worse: Overall survival drops to less than 10 months. …

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06344130 on ClinicalTrials.gov

8. Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

   This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patien…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Hideho Okada, MD, PhD

   See if you can join NCT06186401 on ClinicalTrials.gov

9. A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial

   This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at center…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Locations

   2 in total

   Run by

   Mayo Clinic

   See if you can join NCT07074756 on ClinicalTrials.gov

10. A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

    This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    4 in total

    Run by

    Duke University

    See if you can join NCT06069726 on ClinicalTrials.gov

11. Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

    Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells. Objective: To test LMP744 in peop…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Neurological Disorders and Stroke (NINDS)

    See if you can join NCT07416188 on ClinicalTrials.gov

12. Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma

    The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI). That spectroscopic MRI scan will be used to increase the area of the brain receiving radiation and then the dose of radiation in a…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT05284643 on ClinicalTrials.gov

13. Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

    A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma

    Stage

    Not phased

    Ages

    18 to 85

    Site

    Honor Health, Scottsdale, Arizona

    Locations

    3 in total

    Run by

    Alpha Tau Medical LTD.

    See if you can join NCT06910306 on ClinicalTrials.gov

14. MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

    This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT03896568 on ClinicalTrials.gov

15. CARv3-TEAM-E T Cells in Glioblastoma

    The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital Cancer Center, Boston, Massachusetts

    Run by

    Marcela V. Maus, M.D.,Ph.D.

    See if you can join NCT05660369 on ClinicalTrials.gov

16. Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

    This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT06815029 on ClinicalTrials.gov

17. Sitagliptin in Recurrent/Progressive Grade 4 Glioma

    Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Iowa Health Care, Iowa City, Iowa

    Run by

    Kailin Yang, MD, PhD

    See if you can join NCT07541781 on ClinicalTrials.gov

18. Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

    The goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent Glioblastoma. TGX-007 is a gene therapy drug delivered by a harmless adeno-asso…

    Stage

    Phase 1

    Ages

    18 to 70

    Site

    Ohio State University Hospital, Columbus, Ohio

    Locations

    2 in total

    Run by

    Trogenix ltd

    See if you can join NCT07346144 on ClinicalTrials.gov

19. RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

    This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    UF Health, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT06389591 on ClinicalTrials.gov

20. Sonodynamic Therapy in Patients With Recurrent GBM

    Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided low-intensity focused ultrasound (LIFU) for patients who have recurrent GBM. F…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    University of Virginia, Charlottesville, Virginia

    Run by

    Shayan Moosa, MD

    See if you can join NCT06039709 on ClinicalTrials.gov

21. Sacituzumab Govitecan in Recurrent Glioblastoma

    This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

    Locations

    3 in total

    Run by

    The University of Texas Health Science Center at San Antonio

    See if you can join NCT04559230 on ClinicalTrials.gov

22. CUE-102 in Recurrent Glioblastoma

    The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    2 in total

    Run by

    David Reardon, MD

    See if you can join NCT06917885 on ClinicalTrials.gov

23. Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

    The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06058988 on ClinicalTrials.gov

24. OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

    In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive astrocytoma WHO grade IV.

    Stage

    Phase 2

    Ages

    18 to 90

    Site

    UF Health Shands Hospital, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT06558214 on ClinicalTrials.gov

25. Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

    This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the Uni…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

    Run by

    Jonsson Comprehensive Cancer Center

    See if you can join NCT06090903 on ClinicalTrials.gov